Edition:
India

Bio Rad Laboratories Inc (BIO.N)

BIO.N on New York Stock Exchange

506.95USD
10 Aug 2020
Change (% chg)

-- (--)
Prev Close
$506.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
84,027
52-wk High
$539.56
52-wk Low
$315.00

Summary

Name Age Since Current Position

Norman Schwartz

70 2012 Chairman of the Board, President, Chief Executive Officer

Ilan Daskal

54 2019 Chief Financial Officer, Executive Vice President

Andrew Last

60 2019 Chief Operating Officer, Executive Vice President

Timothy Ernst

60 2016 Executive Vice President, General Counsel, Secretary

Michael Crowley

58 2014 Executive Vice President - Global Commercial Operations

Giovanni Magni

63 2014 Executive Vice President, Chief Strategy Officer

Annette Tumolo

65 2017 Executive Vice President, President, Life Science Group

Dara Wright

44 2020 Executive Vice President and President of the Clinical Diagnostics Group

Ajit Ramalingam

47 2020 Senior Vice President, Chief Accounting Officer

Ronald Hutton

62 2012 Vice President, Treasurer

Gregory Hinckley

73 2017 Lead Independent Director

Alice Schwartz

93 1967 Director

Jeffrey Edwards

59 2017 Independent Director

Melinda Litherland

62 2017 Independent Director

Arnold Pinkston

61 2017 Independent Director

Biographies

Name Description

Norman Schwartz

Mr. Norman D. Schwartz is Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Schwartz has been our President and Chief Executive Officer since 2003 and our Chairman of the Board since 2012. He was our Vice President from 1989 to 2002, our Group Manager, Life Science, from 1997 to 2002 and our Group Manager, Clinical Diagnostics, from 1993 to 1997. We believe Mr. Schwartz’s financial and business expertise gained through over 43 years of service with our Company, including as our President and Chief Executive Officer for over 17 years, give him the qualifications and skills to serve as a director.

Ilan Daskal

Mr. Ilan Daskal serves as Chief Financial Officer, Executive Vice President of the Company effective April 6, 2019. He was appointed Executive Vice President and Chief Financial Officer, effective April 6, 2019. Prior to joining Bio-Rad, Mr. Daskal, was the Chief Financial Officer of Lumileds, a global leader in advanced lighting technology, from May 2017 to January 2019. From 2015 through 2016, Mr. Daskal held multiple short-term Chief Financial Officer roles with private and public companies including Aricent Inc., a global design and engineering company, Cepheid, a molecular diagnostic company, and SunEdison Inc., a renewable energy company. Prior to that, from 2008 to 2015, Mr. Daskal was the Executive Vice President and Chief Financial Officer at International Rectifier Corporation, a leader in power management semi-conductor technology that was publicly traded until it was acquired by Infineon Technologies in 2015. Mr. Daskal also currently serves on the Board of Directors of Natus Medical Incorporated, a publicly traded provider of medical device solutions.

Andrew Last

Dr. Andrew J. Last Ph.D. serves as Chief Operating Officer, Executive Vice President of the Company. Andrew J. Last was appointed Executive Vice President and Chief Operating Officer, effective April 22, 2019. Prior to joining Bio-Rad, Dr. Last was the Chief Commercial Officer of Berkeley Lights, Inc., a digital cell biology company that develops and commercializes platforms for the acceleration of discovery, development and delivery of cell-based products and therapies, from December 2017 to April 2019. From 2016 through 2017, Dr. Last was the Chief Operating Officer of Intrexon Corporation, a publicly traded biotechnology company. Prior to that, from 2010 to 2016, Dr. Last held senior roles at Affymetrix, Inc., a company that manufactures DNA microarray solutions, including most recently the role of Executive Vice President and Chief Operating Officer. Dr. Last’s other previous global leadership roles have included senior positions with Becton, Dickinson and Company from 2004 to 2010; Applied Biosystems from 2002 to 2004; Incyte Genomics from 1999 to 2002; and Monsanto Company from 1987 to 1999. Dr. Last also currently serves on the Board of Directors of OncoCyte Corporation, a publicly traded molecular diagnostics company.

Timothy Ernst

Mr. Timothy Scott Ernst is Executive Vice President, General Counsel, Secretary of the Company. He was appointed Executive Vice President, General Counsel and Secretary in June 2016. Previously he was Senior Vice President, General Counsel and Secretary of Big Heart Pet Brands, a manufacturer and marketer of branded pet food products, from 2014 to 2015. Prior to that, he was the Senior Vice-President, General Counsel and Secretary of Del Monte Foods, a manufacturer and marketer of consumer food products, from 2012 to 2014, and Associate General Counsel and Assistant Secretary of Del Monte Foods from 1995 to 2012. He was the Associate General Counsel of California and Hawaiian Sugar Company, a refiner and marketer of sugar and sugar products, from 1990 to 1995. He is a member of the California Bar and Association of Corporate Counsel.

Michael Crowley

Mr. Michael Crowley is Executive Vice President - Global Commercial Operations of the Company. He was appointed Executive Vice President, Global Commercial Operations in December 2014. Previously he was Vice President, Commercial Manager, Europe from 2012 to 2014 and Commercial Manager, Clinical Diagnostics Group, Europe from 2011 to 2012 and Division Manager of the Clinical Diagnostics Group North American Sales Organization from 2008 to 2011. Prior to that, he was the Clinical Diagnostics U.S. National Sales Manager since joining Bio-Rad in 1998.

Giovanni Magni

Mr. Giovanni Magni is Executive Vice President, Chief Strategy Officer of the Company. He was appointed Executive Vice President, Chief Strategy Officer in August 2014. Previously, he was Executive Vice President of International Sales from 2012 to 2014 and Vice President and International Sales Manager from 2004 to 2012. Prior to that, he held various positions within Bio-Rad since joining us in 1995, including Diagnostic Division Manager, Southern Europe and Diagnostics Group Operation Manager, France.

Annette Tumolo

Ms. Annette Tumolo serves as Executive Vice President, President, Life Science Group of the Company. She was appointed Executive Vice President, President, Life Science Group in September 2017. Previously she was Executive Vice President and General Manager of the Digital Biology Group from 2015 to 2017, Senior Vice President of the Digital Biology Center from 2014 to 2015, and Vice President, Director of the Digital Biology Center from 2012 to 2014. Prior to that she held various positions within Bio-Rad since joining us in 1989, including Vice President and Division Manager of the Gene Expression Division, and Business Unit Manager of the Molecular Biology Business Unit.

Dara Wright

Ms. Dara Grantham Wright serves as Executive Vice President and President of the Clinical Diagnostics Group of the Company. She was appointed Executive Vice President, President, Clinical Diagnostics Group effective January 1, 2020. Prior to joining Bio-Rad, from 2016 to November 2019 Ms. Grantham Wright was Vice President and General Manager, Biosciences Division, Life Science Solutions Group, Protein & Cell Analysis at Thermo Fisher Scientific Inc., a biotechnology product development company. From 2014 to 2016, Ms. Grantham Wright was Senior Vice President & General Manager, eBioscience Business Unit at Affymetrix, Inc., a manufacturer of DNA microarrays that was acquired by Thermo Fisher Scientific in 2016. Prior to that, from 2013 to 2014, she was Chief Commercial Officer at Boreal Genomics, Inc., a company that develops new technologies for blood-based detection and monitoring of circulating tumor DNA. From 2010 to 2013 she was Global Vice President of Strategic Marketing and Clinical Applications at Affymetrix, Inc.

Ajit Ramalingam

Mr. Ajit Ramalingam serves as Senior Vice President, Chief Accounting Officer of the Company. Mr. Ramalingam has over twenty years of experience in accounting and financial management roles. Prior to joining the Company, Mr. Ramalingam, age 47, was the Vice President & Corporate Controller of Logitech, Inc., a manufacturer of computer peripherals and software, from October 2018 to March 2020. From 2016 through 2018, Mr. Ramalingam was the AVP Worldwide Controller of BroadSoft, Inc., a global communication software and service provider that was purchased by Cisco Systems in 2018, and from 2013 to 2016 he was the Senior Director, US Controller of BroadSoft. Prior to that, from 2005 to 2012, Mr. Ramalingam worked at PricewaterhouseCoopers, LLP as Senior Manager, Assurance.

Ronald Hutton

Mr. Ronald W. Hutton is Vice President, Treasurer of the Company. He has been our Treasurer since 1997 and was appointed Vice President in 2012. Previously, he was Director of Treasury at Kaiser Aluminum & Chemical Corporation from 1993 to 1997.

Gregory Hinckley

Mr. Gregory K. Hinckley CPA serves as Lead Independent Director of the Company. Mr. Hinckley retired from Mentor Graphics Corporation, a leader in computer automated software for electronics design, in July 2017 after 20 years at Mentor Graphics. From 1999 to July 2017, he served as President of Mentor Graphics. From 1997 to 1999, he served as Mentor Graphics’ Executive Vice President, Chief Operating and Financial Officer. Prior to joining Mentor Graphics in 1997, Mr. Hinckley served as Chief Financial Officer for VLSI Technology, Inc., a publicly traded integrated semiconductor device company, from 1992-1997, for Crowley Maritime Corporation from 1989-1991 and for Bio-Rad from 1983-1989. He currently serves as a director and on the Audit Committee of SI-BONE, Inc., a publicly traded orthopedic device company. Mr. Hinckley also serves as a trustee of Claremont McKenna College and Portland State University where he is Chair of the board. Mr. Hinckley previously served as a director for several other publicly traded companies including Intermec, Inc., a publicly traded provider of automated identification and data collection (AIDC) solutions, Super Micro, a publicly traded provider of advanced computer server systems and subsystems, and Amkor Technology, a leading supplier of outsourced semiconductor interconnect services. Mr. Hinckley has over 40 years of public company experience. We believe that Mr. Hinckley’s financial, operational and public board expertise give him the qualifications and skills to serve as a director.

Alice Schwartz

Mrs. Alice N. Schwartz is Director of the Company. Mrs. Schwartz has been retired since 1979. From 1972 to 1978 she was a Research Associate at the University of California. As a co-founder of our Company, Mrs. Schwartz has a unique and invaluable understanding of our Company’s business practices and core values. We believe that Mrs. Schwartz’s technical and business expertise gained through her many years as a researcher and as a director of our Company give her the qualifications and skills to serve as a director.

Jeffrey Edwards

Mr. Jeffrey L. Edwards serves as Independent Director of the Company. Mr. Edwards retired from Allergan, Inc., a multi-specialty health care company, in February 2015 after nearly 22 years at Allergan. From September 2005 to August 2014, he served as Executive Vice President, Finance and Business Development, Chief Financial Officer at Allergan. From 2003 to 2005 he served as Allergan’s Corporate Vice President, Corporate Development and previously served as Senior Vice President, Treasury, Tax and Investor Relations. Prior to joining Allergan, Mr. Edwards was with Banque Paribas from 1992-1993 and Security Pacific National Bank from 1983-1992, where he held various senior-level positions in the credit and business development functions. Mr. Edwards currently serves on the Board of Directors and as Audit Committee Chair of FibroGen, Inc., a publicly traded biopharmaceutical company, and on the Board of Directors, the Compensation Committee and the Audit Committee of Clearside Biomedical, Inc., a publicly traded development stage pharmaceutical company. Mr. Edwards has over 25 years of public company experience. We believe that Mr. Edwards’ deep financial, capital allocation, and business development experience give him the qualifications and skills to serve as a director.

Melinda Litherland

Ms. Melinda Litherland serves as Independent Director of the Company. Ms. Litherland retired in 2015 as a Partner at Deloitte & Touche LLP, where she worked since 1981. She is a certified public accountant with 34 years of experience working with life science and technology companies in both audit and consulting capacities. Ms. Litherland is a member of the American Institute of CPAs (AICPA) and previously served for 12 years on the Board of Directors of Ronald McDonald House Charities Bay Area, including serving on the Finance Committee. We believe that Ms. Litherland’s extensive financial and life sciences background gives her the qualifications and skills to serve as a director.

Arnold Pinkston

Mr. Arnold A. Pinkston serves as Independent Director of the Company. Mr. Pinkston is currently the Corporate Vice President, General Counsel of Edwards Lifesciences Corporation, a global leader in patient-focused medical innovations for heart disease, as well as critical care and surgical monitoring. Prior to joining Edwards in July 2019, he served as the Chief Legal Officer and Corporate Secretary of CoreLogic, Inc., a leading global property information, analytics and data-enabled solutions provider from January 2018 until June 2019. From 2011 until March 2015, he served as Executive Vice President and General Counsel for Allergan, Inc., a multi-specialty health care company. From 2005 until 2011, Mr. Pinkston served as Senior Vice President, General Counsel and Secretary for Beckman Coulter, Inc., a health care diagnostics and life sciences company. From 1994 until 2005, he held various positions at Eli Lilly and Company, a global pharmaceutical company, including Vice President and Deputy General Counsel. Additionally, Mr. Pinkston was formerly a director of Janus Capital Group, a publicly owned investment firm. Mr. Pinkston has over 25 years of experience at successful public companies. We believe that Mr. Pinkston’s broad corporate governance, regulatory and M&A knowledge give him the qualifications and skills to serve as a director.

Basic Compensation